Repatha Dosing May Be Disadvantage In PCSK9 Race With Praluent
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen picked two dosing regimens based on patient preferences, but FDA says providers may want more flexibility for dose adjustments to fit LDL-C goals.